LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report

BackgroundRearrangements of the anaplastic lymphoma kinase (ALK) gene comprise a small subset of non-small cell lung cancer (NSCLC). Patients with NSCLC harboring ALK fusion proteins are sensitive to ALK tyrosine kinase inhibitors (TKIs). Various fusion partners of ALK are being discovered with the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yanlong Yang, Hongbo Zheng, Zizhe Li, Shuchen Shi, Lang Zhong, Longlong Gong, Bin Lan
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2022-05-01
Edice:Frontiers in Oncology
Témata:
LMO7-ALK fusion
crizotinib
NSCLC
case report
LUAD
On-line přístup:https://www.frontiersin.org/articles/10.3389/fonc.2022.841493/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky